eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
2/2018
vol. 14
 
Share:
Share:
more
 
 
abstract:
Basic research

Expression of selected genes of dendritic and Treg cells in blood and skin of morphea patients treated with UVA1 phototherapy

Agnieszka J. Osmola-Mańkowska, Ewa Teresiak-Mikołajczak, Michał J. Kowalczyk, Ryszard W. Żaba, Zygmunt Adamski, Aleksandra Dańczak-Pazdrowska

Arch Med Sci 2018; 14, 2: 361–369
Online publish date: 2018/02/21
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction: Morphea is a chronic autoimmune disease characterized by fibrosis of the skin. Dendritic cells (DC) and regulatory T cells (Tregs) play a significant role in development of autoimmune and tolerance mechanisms. The aim of the study was to establish the expression of selected genes of plasmacytoid and myeloid DC, Treg cells, and the microenvironment of cytokines (interleukin-17A (IL-17A), transforming growth factor  (TGF-)) in blood and skin of morphea patients. In addition, the effect of UVA1 phototherapy on expression of the aforementioned genes was evaluated.

Material and methods: The study was performed on 15 blood and 10 skin samples from patients with morphea. The evaluation included expression of CLEC4C (C-type lectin domain family 4, member C receptor), Lymphocyte antigen 75 (LY75), Forkhead box p3 (foxp3) transcription factor, IL-17A and TGF- genes in peripheral blood mononuclear cells (PBMC) and in skin samples both before and after UVA1 phototherapy using real-time polymerase chain reaction.

Results: The study revealed lower expression of CLEC4C before (p = 0.010) and after (p = 0.009) phototherapy and lower expression of IL-17A before (p = 0.038) phototherapy in PBMC of patients with morphea vs. the control group. Expression of CLEC4C in PBMC correlated negatively (rho = –0.90; p = 0.001) with activity of disease after phototherapy. No significant differences were found between expression of analysed genes before and after UVA1 therapy in PBMC and skin of morphea patients.

Conclusions: The results do not confirm the involvement of analysed subsets of DC and Tregs in UVA1 phototherapy in morphea, but point to CLEC4C as a possible biomarker associated with the disease activity.
keywords:

regulatory T cells, plasmacytoid dendritic cells, myeloid dendritic cells

references:
Fett N. Scleroderma: nomenclature, etiology, pathogenesis, prognosis and treatments: Facts and controversies. Clin Dermatol 2013; 31: 432-7.
Shrimpton RE, Butler M, Morel AS, et al. CD205 (DEC-205): a recognition receptor for apoptotic and necrotic self. Mol Immunol 2009; 46: 1229-39.
Dzionek A, Sohma Y, Nagafune J, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 2001; 194: 1823-34.
Blanco P, Palucka AK, Pascual V. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 2008; 19: 41-52.
Gołąb J, Jakóbisiak M, Lasek W, Stokłosa T. Immunology. Wydawnictwo Naukowe PWN, Warsaw 2007; 376-95.
Kurasawa K, Hirose K, Sano H, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43: 2455-63.
Murata M, Fujimoto M, Matsushita T, et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci 2008; 50: 240-2.
York NR, Jacobe HT. UVA1 phototherapy: a review of mechanism and therapeutic application. Int J Dermatol 2010; 49: 623-30.
Arkachaisri T, Vilaiyuk S, Torok KS, Medsger TA. Development and initial validation of the Localized Scleroderma Skin Damage Index and Physician Global Assessment of disease damage: a proof-of-concept study. Rheumatology 2010; 49: 373-81.
Gilmour TK, Wilkinson B, Biret SN, et al. Analysis of dendritic cell populations using a revised histological staging of morphea. Br J Dermatol 2000; 143: 1183-92.
Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
Kowalczyk MJ, Dańczak-Pazdrowska A, Szramka-Pawlak B, Żaba R, Silny W, Osmola-Mańkowska A. Expression of selected human endogenous retroviral sequences in skin and peripheral blood mononuclear cells in morphea. Arch Med Sci 2012; 8: 819-25.
Pattyn F, Speleman F, De Paepe A, Vandesompele J. RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res 2003; 31: 122-3.
Wollenberg A, Wagner M, Günther S. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002; 119: 1096-102.
Ghoreishi M, Kellet CV, Dutz JP. Type I IFN-induced protein MxA and plasmocytoid dendritic cells in lesions of morphea. Exp Dermatol 2012; 21: 417-9.
Cederblad B, Blomberg S, Vallin H, Perers A, Alm GV, Ronnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha-producing cells. J Autoimmun 1998; 11: 465-70.
Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001; 159: 237-43.
Antiga E, Quaglino P, Bellandi S, et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol 2010; 162: 1056-63.
Dańczak-Pazdrowska A, Kowalczyk MJ, Szramka-Pawlak B, et al. Transforming growth factor-beta1 in plaque morphea. Postep Dermatol Alergol 2013; 30: 337-42.
Klein S, Kretz CC, Ruland V, et al. Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann Rheum Dis 2011; 70: 1475-81.
Dańczak-Pazdrowska A, Kowalczyk M, Szramka-Pawlak B, et al. Interleukin-17A and interleukin-23 in morphea. Arch Med Sci 2012; 8: 1089-95.
Duthie MS, Kimber I, Dearman RJ, Norval M. Differential effects of UVA1 and UVB radiation on Langerhans cell migration in mice. J Photochem Photobiol B 2000; 57: 123-31.
Camacho NR, Sanchez JE, Martin RF, Gonzalez JR, Sanchez JL. Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells. J Am Acad Dermatol 2001; 45: 697-9.
Papp G, Horvath IF, Barath S, et al. Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. Clin Immunol 2012; 142: 150-9.
Singh TP, Schon MP, Wallbrecht K, et al. 8-methoxy­psoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 2010; 184: 7257-67.
Schnopp C, Rad R, Weidinger A, et al. Fox-P3-positive regulatory T cells are present in the skin of generalized atopic eczema patients and are not particularly affected by medium-dose UVA1 therapy. Photodermatol Photoimmunol Photomed 2007; 23: 81-5.
Wojas-Pelc A, Wielowieyska-Szybinska D, Kieltyka A. Presence of the antinuclear antibodies and antibodies to Borrelia burgdorferi among patients with morphea en plaque, deep linear scleroderma and atrophoderma Pasini-Pierini. Przegl Lek 2002; 59: 898-902.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe